Cas9 Stable Cell Line - ACHN

The Cas9-Stable Cell Line—ACHN is a genetically engineered cell line derived from the human renal adenocarcinoma cell line, ACHN. This specialized cell line is capable of stably expressing the Cas9 nuclease, a critical component of the CRISPR-Cas9 genome editing system. The parental ACHN cell line originates from a renal tumor and exhibits an epithelial cell morphology, rendering it highly valuable for studying the biology of renal cancer and its response to therapeutic agents. The stable integration of the Cas9 gene ensures the consistency and high efficiency of the genome editing process, eliminating the need for transient transfection and thereby effectively reducing variability in experimental results. Even after undergoing numerous passages, this cell line retains robust growth vitality and potent genome editing capabilities.

In the field of functional genomics, researchers frequently utilize this cell line to conduct high-throughput CRISPR screens aimed at identifying key genes involved in the pathogenesis, metastasis, and drug resistance mechanisms of renal cancer. By introducing guide RNAs (gRNAs) targeting specific genes, scientists can generate gene knockout models to validate the functions of oncogenes or tumor suppressor genes within the context of renal cancer development. Pharmaceutical companies employ this cell line for drug target validation and compound screening; through the application of genome editing techniques, they are able to gain deeper insights into the mechanisms of action of novel therapeutic agents. Furthermore, this cell line facilitates research into "synthetic lethality" effects, thereby enabling the exploration of combination therapy strategies tailored for precision oncology.